Anticipate Debate About Aducanumab for Alzheimer's Disease
August 2021
You'll hear controversy about aducanumab (Aduhelm), the first new med for Alzheimer's disease in almost 20 years.
It's different than other Alzheimer's meds (donepezil, etc).
Aducanumab is a monoclonal antibody given as an IV infusion every 4 weeks...and it's intended to target and affect the underlying disease.
Practical advice for a better career, with unlimited access to CE
Hospital Pharmacy Technician's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote